Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial

Revision as of 05:11, 16 February 2009 by Jacki Buros (talk | contribs) (Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial moved to News:Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Redirect page

Jump to navigation Jump to search

Redirect to:

News:Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial

Retrieved from "https://www.wikidoc.org/index.php?title=Bivalirudin_during_primary_PCI_reduces_major_bleeding_and_adverse_events_at_30_days_in_the_HORIZONS-AMI_trial&oldid=532443"

Cookies help us deliver our services. By using our services, you agree to our use of cookies.